CH681691A5 - - Google Patents

Download PDF

Info

Publication number: CH681691A5
Authority: CH; Switzerland
Prior art keywords: radical; carbon atoms; microspheres; hydrogen atom; aikyl
Prior art date: 1989-11-15

Application number

CH3611/90A

Other languages

English (en)

French (fr)

Inventor

Gerard Cohen

Jean-Luc Dubois

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-15

Filing date

1990-11-14

Publication date

1993-05-14

1990-11-14 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1993-05-14 Publication of CH681691A5 publication Critical patent/CH681691A5/fr

Links

239000004005 microsphere Substances 0.000 claims description 57
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 50
150000003254 radicals Chemical class 0.000 claims description 50
125000004432 carbon atom Chemical group C* 0.000 claims description 48
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
229920001577 copolymer Polymers 0.000 claims description 30
-1 hydrocarbon radical Chemical class 0.000 claims description 25
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 24
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
150000003431 steroids Chemical class 0.000 claims description 17
230000001833 anti-estrogenic effect Effects 0.000 claims description 15
239000000328 estrogen antagonist Substances 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 12
DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
239000012074 organic phase Substances 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
239000008346 aqueous phase Substances 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 6
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
238000003756 stirring Methods 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 5
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 4
239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000000732 arylene group Chemical group 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 4
230000008020 evaporation Effects 0.000 claims description 4
150000002576 ketones Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000006017 1-propenyl group Chemical group 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 claims description 2
150000000795 D-homosteroids Chemical group 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000000304 alkynyl group Chemical group 0.000 claims description 2
229940046836 anti-estrogen Drugs 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 2
XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical compound C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
229930195733 hydrocarbon Natural products 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
RDKRLZMGGDOEPU-UHFFFAOYSA-N n-methyl-8-phenyloctanamide Chemical compound CNC(=O)CCCCCCCC1=CC=CC=C1 RDKRLZMGGDOEPU-UHFFFAOYSA-N 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims description 2
239000012071 phase Substances 0.000 claims description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
229940102213 injectable suspension Drugs 0.000 claims 2
238000001035 drying Methods 0.000 claims 1
239000004310 lactic acid Substances 0.000 claims 1
235000014655 lactic acid Nutrition 0.000 claims 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
229920000053 polysorbate 80 Polymers 0.000 claims 1
238000005507 spraying Methods 0.000 claims 1
238000005406 washing Methods 0.000 claims 1
238000011282 treatment Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
208000030499 combat disease Diseases 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CH3611/90A 1989-11-15 1990-11-14 CH681691A5 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR898914976A FR2654337B1 (fr)	1989-11-15	1989-11-15	Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.

Publications (1)

Publication Number	Publication Date
CH681691A5 true CH681691A5 (da)	1993-05-14

Family

ID=9387417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3611/90A CH681691A5 (da)	1989-11-15	1990-11-14

Country Status (13)

Country	Link
JP (1)	JPH03294229A (da)
AT (1)	AT400298B (da)
BE (1)	BE1005511A4 (da)
CA (1)	CA2029940A1 (da)
CH (1)	CH681691A5 (da)
DE (1)	DE4036425A1 (da)
DK (1)	DK270990A (da)
FR (1)	FR2654337B1 (da)
GB (1)	GB2239798B (da)
IT (1)	IT1242010B (da)
LU (1)	LU87836A1 (da)
NL (1)	NL9002492A (da)
SE (1)	SE9003570L (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU222501B1 (hu) *	1991-06-28	2003-07-28	Endorecherche Inc.	MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) *	1991-06-28	1993-12-29	Endorecherche Inc	Controlled release systems and low dose androgens
RU2128055C1 (ru) *	1992-12-07	1999-03-27	Такеда Кемикал Индастриз Лтд.	Фармацевтическая композиция замедленного высвобождения и способ ее получения
DE69405491T2 (de) *	1993-06-24	1998-02-19	Lilly Co Eli	Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US5910492A (en) *	1995-06-05	1999-06-08	Takeda Chemical Industries, Ltd.	Osteogenic promoting pharmaceutical composition
EP2210585A1 (en)	2009-01-16	2010-07-28	Exelgyn	SPRM pharmaceutical compositions methods of treatment using them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4293539A (en) *	1979-09-12	1981-10-06	Eli Lilly And Company	Controlled release formulations and method of treatment
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) *	1982-06-11	1985-07-19	Roussel Uclaf	Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4530840A (en) *	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
FR2537980B1 (fr) *	1982-12-17	1986-12-19	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
ES533260A0 (es) *	1983-06-15	1985-02-01	Schering Ag	Procedimiento para la preparacion de 13a-alquilgonanos
GB8327256D0 (en) *	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) *	1984-06-29	1987-03-06	Roussel Uclaf	Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
CA1256638A (en) *	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
FR2573657B1 (fr) *	1984-11-29	1989-05-12	Roussel Uclaf	Produit comprenant une substance antiprogestomimetique et une substance uterotonique
DE3533175A1 (de) *	1985-09-13	1987-03-19	Schering Ag	Antigestagene zur verschiebung der endometrialen reifung
FR2596395B1 (fr) *	1986-03-26	1989-05-26	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4758435A (en) *	1986-08-11	1988-07-19	American Cyanamid Company	Estradiol implant composition and method for preparation
DE3633244A1 (de) *	1986-09-26	1988-03-31	Schering Ag	Antigestagene zur hemmung der uterinen prostaglandinsynthese
EP0310542B1 (de) *	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) *	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE3744054A1 (de) *	1987-12-21	1989-06-29	Schering Ag	Verwendung von antigestagenen zur herstellung von arzneimitteln
BE1004905A4 (fr) *	1987-12-30	1993-02-23	Roussel Uclaf	Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法

1989
- 1989-11-15 FR FR898914976A patent/FR2654337B1/fr not_active Expired - Fee Related
1990
- 1990-11-08 LU LU87836A patent/LU87836A1/fr unknown
- 1990-11-09 SE SE9003570A patent/SE9003570L/ not_active Application Discontinuation
- 1990-11-09 BE BE9001062A patent/BE1005511A4/fr not_active IP Right Cessation
- 1990-11-13 DK DK270990A patent/DK270990A/da not_active Application Discontinuation
- 1990-11-13 IT IT48470A patent/IT1242010B/it active IP Right Grant
- 1990-11-14 CA CA002029940A patent/CA2029940A1/fr not_active Abandoned
- 1990-11-14 JP JP2306374A patent/JPH03294229A/ja active Pending
- 1990-11-14 CH CH3611/90A patent/CH681691A5/fr not_active IP Right Cessation
- 1990-11-15 AT AT0231390A patent/AT400298B/de not_active IP Right Cessation
- 1990-11-15 DE DE4036425A patent/DE4036425A1/de not_active Withdrawn
- 1990-11-15 NL NL9002492A patent/NL9002492A/nl not_active Application Discontinuation
- 1990-11-15 GB GB9024862A patent/GB2239798B/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATA231390A (de)	1995-04-15
CA2029940A1 (fr)	1991-05-16
DK270990D0 (da)	1990-11-13
BE1005511A4 (fr)	1993-08-31
FR2654337B1 (fr)	1994-08-05
GB9024862D0 (en)	1991-01-02
IT9048470A1 (it)	1992-05-13
LU87836A1 (fr)	1991-05-07
DK270990A (da)	1991-05-16
SE9003570D0 (sv)	1990-11-09
FR2654337A1 (fr)	1991-05-17
IT9048470A0 (it)	1990-11-13
GB2239798B (en)	1993-10-27
JPH03294229A (ja)	1991-12-25
IT1242010B (it)	1994-02-02
AT400298B (de)	1995-11-27
SE9003570L (sv)	1991-05-16
DE4036425A1 (de)	1991-05-16
GB2239798A (en)	1991-07-17
NL9002492A (nl)	1991-06-03

Legal Events

Date	Code	Title	Description
1999-07-15	PL	Patent ceased

Publication	Publication Date	Title
EP0665752B1 (fr)	2003-06-04	Compositions pharmaceutiques contenant des derives de steroides naturels 3beta hydroxyles et leur utilisation
BE1005696A3 (fr)	1993-12-21	Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation.
FR2537980A1 (fr)	1984-06-22	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
WO1991015193A1 (fr)	1991-10-17	Microspheres, leur procede de preparation et leur utilisation
EP0280618B1 (fr)	1992-09-30	Nouveaux 19-nor stéroîdes substitués en position 7, leur préparation, leur application comme médicaments, les compositions pharmaceutiques les renfermant
WO2018197731A1 (fr)	2018-11-01	Extrait de 20-hydroxyecdysone de qualité pharmaceutique, son utilisation et sa préparation
BE1005511A4 (fr)	1993-08-31	Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant.
WO2003004024A1 (en)	2003-01-16	Injectable sustained-release microspheres of huperzine a compounds
WO1998048802A1 (fr)	1998-11-05	Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
LU84439A1 (fr)	1983-06-13	Nouveaux derives du 3-amino pregn-5-ene,leurs sels,leur preparation,leur application a titre de medicaments et les compositions les renfermant
FR2571617A1 (fr)	1986-04-18	Procede pour la microencapsulation par separation de phases de substances medicamenteuses hydrosolubles
FR2684101A1 (fr)	1993-05-28	Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
CH637397A5 (fr)	1983-07-29	Imidazobenzoxazines et leurs sels, procedes de preparation et compositions pharmaceutiques.
BE1001687A5 (fr)	1990-02-06	Composition a base de polyesters pour la liberation controlee de substances medicamenteuses.
BE898430A (fr)	1984-06-12	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation.
EP0101383B1 (fr)	1986-11-12	Dérivés d'amino-14 stéroides, application en thérapeutique, et procédé de préparation
FR2801055A1 (fr)	2001-05-18	Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
CH620688A5 (en)	1980-12-15	Process for the preparation of new lactones derived from cyclopentanol
CH619470A5 (en)	1980-09-30	Process for the preparation of 2-(2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L-seryl-D-iso glutamine and 2-(2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L-seryl-D-glu tamic acid
CN1283451A (zh)	2001-02-14	含有生育酚的局部组合物
FR2648814A1 (fr)	1990-12-28	L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique
EP0032889B1 (fr)	1984-02-15	Nouveaux dérivés du type diméthyl-1,10 oxayohimbane et médicaments les contenant
WO2004016580A2 (fr)	2004-02-26	Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
CH646182A5 (fr)	1984-11-15	Derive du 5-pregnan-20-ol et ses sels avec les acides, leur preparation et medicaments les renfermant.
FR2548191A1 (fr)	1985-01-04	Amino-14 steroides, application en therapeutique et procede de preparation